{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:49:53Z","timestamp":1693662593031},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In this retrospective study, we evaluated the diagnostic accuracy of molecular tests (MT) for the detection of DR\u2010TB, compared to the gold standard liquid\u2010based drug susceptibility testing (DST) in Karakalpakstan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 6670 specimens received in the Republican TB No 1 Hospital Laboratory of Karakalpakstan between January and July 2017 from new and retreatment patients were analysed. Samples were tested using Xpert MTB\/RIF and line probe assays (LPA) for the detection of mutations associated with resistance. The sensitivity and specificity of MTs were calculated relative to results based on DST.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The accuracy of MT for detection of rifampicin resistance was high, with sensitivity and specificity over 98%. However, we observed reduced sensitivity of LPA for detection of resistance; 86% for isoniazid (95% CI 82\u201390%), 86% for fluoroquinolones (95% CI 68\u201096%), 70% for capreomycin (95% CI 46\u201388%) and 23% for kanamycin (95% CI 13\u201335%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We show that MTs are a useful tool for rapid and safe diagnosis of DR\u2010TB; however, clinicians should be aware of their limitations. Although detection of rifampicin resistance was highly accurate, our data suggest that resistance mutations circulating in the Republic of Karakalpakstan for other drugs were not detected by the methods used here. This merits further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13543","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T14:33:00Z","timestamp":1610116380000},"page":"421-427","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Accuracy of molecular drug susceptibility testing amongst tuberculosis patients in Karakalpakstan, Uzbekistan"],"prefix":"10.1111","volume":"26","author":[{"given":"Horacio","family":"Gil","sequence":"first","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF) Nukus Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasmik","family":"Margaryan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF) Nukus Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismailov","family":"Azamat","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF) Nukus Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekturdieva","family":"Ziba","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF) Nukus Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halmuratov","family":"Bayram","sequence":"additional","affiliation":[{"name":"Republican TB No 1 Hospital Laboratory of Karakalpakstan Nukus Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirimqul","family":"Nazirov","sequence":"additional","affiliation":[{"name":"Republican TB No 1 Hospital of Karakalpakstan Nukus Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Gomez","sequence":"additional","affiliation":[{"name":"MSF Amsterdam Holland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatinder","family":"Singh","sequence":"additional","affiliation":[{"name":"MSF Tashkent Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayfutdinov","family":"Zayniddin","sequence":"additional","affiliation":[{"name":"Tuberculosis Institute Tashkent Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nargiza","family":"Parpieva","sequence":"additional","affiliation":[{"name":"National Tuberculosis Reference Laboratory Tashkent Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Achar","sequence":"additional","affiliation":[{"name":"MSF London UK"},{"name":"Karolinska Institutet Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Global Tuberculosis Report 2019.World Health Organisation:Geneva Switzerland2019."},{"key":"e_1_2_6_3_1","unstructured":"The End TB Strategy.World Health Organisation:Switzerland 2014."},{"key":"e_1_2_6_4_1","volume-title":"Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines used in the treatment of Drug\u2010Resistant Tuberculosis","year":"2018"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05903-11"},{"key":"e_1_2_6_6_1","first-page":"CD009593","article-title":"Xpert(R) MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults","author":"Steingart KR","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-12"},{"key":"e_1_2_6_8_1","volume-title":"WHO Treatment Guidelines for Drug\u2010resistant Tuberculosis","year":"2016"},{"key":"e_1_2_6_9_1","unstructured":"Clinical guidelines on drug sensitive and drug resistant tuberculosis.Ministry of Health of Republic of Karakakalpakstan and M\u00e9decins Sans Fronti\u00e8res:Karakalpakstan Uzbekistan;2017."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01463-09"},{"key":"e_1_2_6_11_1","unstructured":"GenoType MTBDRsl VER 1.0 instructions for use.HAIN LifeScience:Nehren Germany 2012."},{"key":"e_1_2_6_12_1","unstructured":"GenoType MTBDRplus VER 2.0 instructions for use.HAIN LifeScience:Nehren Germany 2012."},{"key":"e_1_2_6_13_1","unstructured":"Mycobacteriology Laboratory Manual.Global Laboratory Initiative:Geneva Switzerland 2014."},{"key":"e_1_2_6_14_1","volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug\u2010resistant tuberculosis","year":"2014"},{"key":"e_1_2_6_15_1","volume-title":"R: A Language and Environment for Statistical Computing","year":"2019"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00128-10"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02489-13"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02741-12"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.06.013"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2015.42"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.670-675.2003"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132009000800009"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12476"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874285801408010001"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir406"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00560-14"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01798-18","article-title":"A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin\u2010Resistant Mycobacterium tuberculosis Isolates in a Low\u2010Incidence Setting","volume":"63","author":"Andres S","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.11.3976-3979.2002"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033275"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tmi.13543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T20:47:30Z","timestamp":1693601250000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/tmi.13543"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13543","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"2021-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}